Method for the treatment of premenstrual and other female sexual disorders

• US 20050239798A1
• Filed: 04/04/2005
• Published: 10/27/2005
• Est. Priority Date: 04/22/2004
• Status: Abandoned Application

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: Boehringer Ingelheim Pharmaceuticals Incorporated (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Pyke, Robert
• Application Number:
  US11/097,939
• Publication Number:
  US 20050239798A1
• Time in Patent Office: Days
• US Class Current: 514/254.60
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a method for the treatment of premenstrual and other female sexual disorders comprising the administration of a therapeutically effective amount of flibanserin or a pharmacologically acceptable acid addition salt thereof.

Claims

1. A method for the treatment of premenstrual disorders comprising administering a therapeutically effective amount of flibanserin or a pharmacologically acceptable acid addition salt thereof.

2. The method according to claim 1 for the treatment of premenstrual disorders selected from the group consisting of premenstrual dysphoria, premenstrual syndrome and premenstrual dysphoric disorder.

8. The method according to claim 1 wherein flibanserin is a pharmacologically acceptable acid addition salt thereof selected from a salt formed by an acid selected from succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

13. The method according to claim 1 wherein flibanserin is administered in a dosage range between 0.1 to 400 mg per day.

3. A method for the treatment of sexual aversion disorder in females comprising administering a therapeutically effective amount of flibanserin or a pharmacologically acceptable acid addition salt thereof.

9. The method according to claim 3 wherein flibanserin is a pharmacologically acceptable acid addition salt thereof selected from a salt formed by an acid selected from succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

14. The method according to claim 3 wherein flibanserin is administered in a dosage range between 0.1 to 400 mg per day.

4. A method for the treatment of sexual arousal disorder in females comprising administering a therapeutically effective amount of flibanserin or a pharmacologically acceptable acid addition salt thereof.

10. The method according to claim 4 wherein flibanserin is a pharmacologically acceptable acid addition salt thereof selected from a salt formed by an acid selected from succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

15. The method according to claim 4 wherein flibanserin is administered in a dosage range between 0.1 to 400 mg per day.

5. A method for the treatment of orgasmic disorder in females comprising administering a therapeutically effective amount of flibanserin or a pharmacologically acceptable acid addition salt thereof.

11. The method according to claim 5 wherein flibanserin is a pharmacologically acceptable acid addition salt thereof selected from a salt formed by an acid selected from succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

16. The method according to claim 5 wherein flibanserin is administered in a dosage range between 0.1 to 400 mg per day.

6. A method for the treatment of sexual pain disorders in females comprising administering a therapeutically effective amount of flibanserin or a pharmacologically acceptable acid addition salt thereof.

7. The method according to claim 6 for the treatment of sexual pain disorders selected from the group consisting of dyspareunia, vaginismus, noncoital sexual pain disorder, sexual dysfunction due to a general medical condition and substance-induced sexual dysfunction.

12. The method according to claim 6 wherein flibanserin is a pharmacologically acceptable acid addition salt thereof selected from a salt formed by an acid selected from succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

17. The method according to claim 6 wherein flibanserin is administered in a dosage range between 0.1 to 400 mg per day.